Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 in acute coronary syndrome assessed by IVUS
NL-OMON38390Phase 2Active, not recruiting
- Sponsor
- ABIONYX Pharma
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CER-001 in acute coronary syndrome (ACS), coronary arteriosclerosis and atherosclerosis (4 arms), sponsored by ABIONYX Pharma. Primary endpoint: Nominal change in total plaque volume. Started Sep 2011; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on NL-OMON38390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38390.